U.S. FDA advisers to review Merck’s oral COVID-19 drug next month

Stock Markets31 minutes ago (Oct 14, 2021 02:37PM ET)

(C) Reuters. FILE PHOTO: FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

(Reuters) -A panel of outside advisers to the U.S. health regulator will meet late next month to discuss whether to authorize Merck & Co’s experimental COVID-19 antiviral drug, the agency said on Thursday.

The U.S. Food and Drug Administration’s (FDA) panel will meet on Nov. 30 to discuss safety and effectiveness of the drug, molnupiravir, for the treatment of mild-to-moderate COVID-19 in adults who have tested positive and are at high risk for progression to severe illness. (https://refini.tv/3p1PETq)

The FDA typically follows the advice of its experts but is not bound to do so.

Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir, which it is developing with partner Ridgeback Biotherapeutics. The drug would become the first oral antiviral medication for COVID-19, if cleared by the agency.

Pfizer Inc (NYSE:PFE) and Swiss drugmaker Roche Holding AG (OTC:RHHVF) are also racing to develop an easy-to-administer antiviral pill for the disease.

Merck’s treatment cut the rate of hospitalization and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released earlier this month.

The company has a contract with the U.S. government to supply 1.7 million courses at a price of $700 per course. The drugmaker also recently signed deals with Malaysia and Singapore for supply of the drug.

Bloomberg News first reported on a U.S. FDA advisory committee review of the drug.

U.S. FDA advisers to review Merck’s oral COVID-19 drug next month

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Stories

Enjoying my content?

Join the exclusive subscription today and get premium articles for free

Discover

Supply headaches push down German business morale to six-month...

Economy26 minutes ago (Oct 25, 2021 05:41AM ET) (C) Reuters. FILE PHOTO: Containers are transported...

Huawei CFO Meng Wanzhou returns to work in Shenzhen,...

Stock Markets21 minutes ago (Oct 25, 2021 05:46AM ET) (C) Reuters. FILE PHOTO: Huawei Technologies...

Former Saudi spymaster seeks U.S. help for his jailed...

World42 minutes ago (Oct 25, 2021 05:26AM ET) 3/3 (C) Reuters. Former Saudi intelligence official Saad...

Sudan PM, ministers detained in apparent military coup

2/2 (C) Reuters. FILE PHOTO: Sudan's Prime Minister Abdalla Hamdok and German Chancellor Angela Merkel...

Stocks brace for blockbuster earnings week, pause after 8...

2/2 (C) Reuters. FILE PHOTO: A man wearing a protective face mask, following an outbreak...

HSBC profits rise 74% as economy rebounds from Covid...

HSBC’s profits rose 74% in the third quarter as improving economic conditions allowed the...

Popular Categories